Immunotherapy with adoptive cytomegalovirus-specific T cells transfer: Summarizing latest gene engineering techniques

Area of Science:

• Immunology
• Transplantation Medicine
• Virology

Background:

• Cytomegalovirus (CMV) infection is a major complication after allogeneic hematopoietic stem cell transplantation (HSCT).
• T cell responses are crucial for long-term immunity against CMV, but are impaired during HSCT.
• Adoptive T cell therapy (ACT) using CMV-specific T cells can restore antiviral immunity.

Purpose of the Study:

• To review current strategies for ACT in managing post-transplant CMV infection.
• To introduce novel gene-modified T cell approaches for CMV infection in the context of ACT.

Main Methods:

• Review of existing literature on ACT for CMV infection post-HSCT.
• Discussion of genetic engineering strategies for T cell modification.

Main Results:

• Current ACT methods face limitations including HLA restriction, manufacturing complexity, and donor availability.
• Gene-modified T cells, such as TCR-engineered T cells, present innovative solutions.
• These advancements aim to improve the efficacy and applicability of ACT.

Conclusions:

• Innovations in gene-modified T cells are poised to enhance ACT strategies for combating post-transplant CMV infection.
• Further development of ACT holds significant potential for improving patient outcomes after HSCT.